Hsp90 is a potential risk factor for ovarian cancer prognosis: an evidence of a Chinese clinical center

[1]  M. Kanehisa,et al.  KEGG for taxonomy-based analysis of pathways and genomes , 2022, Nucleic Acids Res..

[2]  Shaozhang Zhou,et al.  Plasmatic Levels of HSP90α at Diagnosis: A Novel Prognostic Indicator of Clinical Outcome in Advanced Lung Cancer Patients Treated With PD-1/PD-L1 Inhibitors Plus Chemotherapy , 2021, Frontiers in Oncology.

[3]  Minoru Kanehisa,et al.  Toward understanding the origin and evolution of cellular organisms , 2019, Protein science : a publication of the Protein Society.

[4]  C. Liang,et al.  The Hypermethylation of Foxp3 Promoter Impairs the Function of Treg Cells in EAP , 2019, Inflammation.

[5]  R. Lothe,et al.  Combination therapies with HSP90 inhibitors against colorectal cancer. , 2019, Biochimica et biophysica acta. Reviews on cancer.

[6]  K. Richter,et al.  Regulation of the Hsp90 system. , 2018, Biochimica et biophysica acta. Molecular cell research.

[7]  A. Jemal,et al.  Ovarian cancer statistics, 2018 , 2018, CA: a cancer journal for clinicians.

[8]  M. Pike,et al.  Timing of births and oral contraceptive use influences ovarian cancer risk , 2017, International journal of cancer.

[9]  Thomas A. Sellers,et al.  Epidemiology of ovarian cancer: a review , 2017, Cancer biology & medicine.

[10]  C. Prodromou.  Mechanisms of Hsp90 regulation , 2016, The Biochemical journal.

[11]  Yukihide Iwamoto,et al.  Elevated expression of HSP90 and the antitumor effect of an HSP90 inhibitor via inactivation of the Akt/mTOR pathway in undifferentiated pleomorphic sarcoma , 2015, BMC Cancer.

[12]  Setia Pramana,et al.  Integration of somatic mutation, expression and functional data reveals potential driver genes predictive of breast cancer survival , 2015, Bioinform..

[13]  Feng-Hou Gao,et al.  Hsp90 Is a Novel Target Molecule of CDDO-Me in Inhibiting Proliferation of Ovarian Cancer Cells , 2015, PloS one.

[14]  Qian Liu,et al.  Heat shock protein 90-β over-expression is associated with poor survival in stage I lung adenocarcinoma patients. , 2015, International journal of clinical and experimental pathology.

[15]  Ji-Eun Lee,et al.  Mitochondrial Hsp90s suppress calcium-mediated stress signals propagating from mitochondria to the ER in cancer cells , 2014, Molecular Cancer.

[16]  F. Ajili,et al.  Prognostic Significance of Heat Shock Protein 90 in Non Muscle Invasive Bladder Cancer Treated by BCG Immunotherapy , 2014 .

[17]  M. Bianchini,et al.  CAMKIIγ, HSP70 and HSP90 transcripts are differentially expressed in chronic myeloid leukemia cells from patients with resistant mutated disease , 2014, Leukemia & lymphoma.

[18]  J. Buchner,et al.  Structure, Function and Regulation of the Hsp90 Machinery , 2013, Biomedical journal.

[19]  S. Soga,et al.  Hsp90 inhibitors as anti-cancer agents, from basic discoveries to clinical development. , 2012, Current pharmaceutical design.

[20]  M. Hance,et al.  Secreted Hsp90 Is a Novel Regulator of the Epithelial to Mesenchymal Transition (EMT) in Prostate Cancer* , 2012, The Journal of Biological Chemistry.

[21]  Rong Biaoxue,et al.  Upregulation of Hsp90-beta and annexin A1 correlates with poor survival and lymphatic metastasis in lung cancer patients , 2012, Journal of experimental & clinical cancer research : CR.

[22]  Jeffrey T. Chang,et al.  Amplification and high-level expression of heat shock protein 90 marks aggressive phenotypes of human epidermal growth factor receptor 2 negative breast cancer , 2012, Breast Cancer Research.

[23]  Walid A Houry,et al.  The role of Hsp90 in protein complex assembly. , 2012, Biochimica et biophysica acta.

[24]  Renaud Seigneuric,et al.  Heat Shock Proteins as Danger Signals for Cancer Detection , 2011, Front. Oncol..

[25]  Kenneth P. Nephew,et al.  Rethinking ovarian cancer: recommendations for improving outcomes , 2011, Nature Reviews Cancer.

[26]  Z. Hořejší,et al.  CK2 phospho-dependent binding of R2TP complex to TEL2 is essential for mTOR and SMG1 stability. , 2010, Molecular cell.

[27]  N. Pavletich,et al.  Tel2 structure and function in the Hsp90-dependent maturation of mTOR and ATR complexes. , 2010, Genes & development.

[28]  M. Fares,et al.  The Effect of Chaperonin Buffering on Protein Evolution , 2010, Genome biology and evolution.

[29]  Doo Jae Lee,et al.  Cytosolic Hsp60 Is Involved in the NF-κB-Dependent Survival of Cancer Cells via IKK Regulation , 2010, PloS one.

[30]  Sung-Won Kim,et al.  Potential prognostic value of heat-shock protein 90 in the presence of phosphatidylinositol-3-kinase overexpression or loss of PTEN, in invasive breast cancers , 2010, Breast Cancer Research.

[31]  Z. Prohászka,et al.  Serum level of soluble 70-kD heat shock protein is associated with high mortality in patients with colorectal cancer without distant metastasis , 2010, Cell Stress and Chaperones.

[32]  L. Frati,et al.  HE4: a new potential early biomarker for the recurrence of ovarian cancer , 2010, Tumor Biology.

[33]  K. West,et al.  Ansamycin inhibitors of Hsp90: nature's prototype for anti-chaperone therapy. , 2009, Current topics in medicinal chemistry.

[34]  G. Coukos,et al.  Immunotherapy opportunities in ovarian cancer , 2008, Expert review of anticancer therapy.

[35]  L. Neckers,et al.  Extracellular heat shock protein 90: A role for a molecular chaperone in cell motility and cancer metastasis , 2007, Cancer science.

[36]  K. Anderson,et al.  Gene expression analysis of B‐lymphoma cells resistant and sensitive to bortezomib * , 2006, British journal of haematology.

[37]  Christopher P Crum,et al.  Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas. , 2005, Cancer research.

[38]  Laurence H Pearl,et al.  Hsp90 and Cdc37 -- a chaperone cancer conspiracy. , 2005, Current opinion in genetics & development.

[39]  W. Stolz,et al.  Induction of Hsp90 protein expression in malignant melanomas and melanoma metastases , 2004, Experimental dermatology.

[40]  I. Yahara.  The role of HSP90 in evolution , 1999, Genes to cells : devoted to molecular & cellular mechanisms.

[41]  Z. Naito,et al.  Expression of hsp90 and cyclin D1 in human breast cancer. , 1999, Cancer letters.

[42]  L. Pearl,et al.  Structural basis for inhibition of the Hsp90 molecular chaperone by the antitumor antibiotics radicicol and geldanamycin. , 1999, Journal of medicinal chemistry.

[43]  S. Lindquist,et al.  Hsp90 as a capacitor for morphological evolution , 1998, Nature.

[44]  C. Kirchhoff.  Molecular characterization of epididymal proteins. , 1998, Reviews of reproduction.

[45]  W. Pratt.  The hsp90-based Chaperone System: Involvement in Signal Transduction from a Variety of Hormone and Growth Factor Receptors , 1998, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[46]  J. Johnson,et al.  A novel chaperone complex for steroid receptors involving heat shock proteins, immunophilins, and p23. , 1994, The Journal of biological chemistry.

[47]  B. Karlan,et al.  OVARIAN CANCER , 2016, Nature Reviews Disease Primers.

[48]  S. Lindquist,et al.  Protein folding sculpting evolutionary change. , 2009, Cold Spring Harbor symposia on quantitative biology.

[49]  W. Pratt,et al.  Chaperoning of glucocorticoid receptors. , 2006, Handbook of experimental pharmacology.

[50]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..

[51]  Susumu Goto,et al.  KEGG: Kyoto Encyclopedia of Genes and Genomes , 2000, Nucleic Acids Res..